Clinical Endocannabinoid Deficiency (CECD) is a condition where an individual produces a lower amount of cannabinoids than experts consider to be essential in the promotion of health, vitality, and well-being.
Scientists now believe CECD may play a role in the following conditions:
- Irritable Bowel Syndrome (IBS)
- Multiple Sclerosis (MS)
- Post-Traumatic Stress Disorder (PTSD)
- Motion Sickness
What Are Endocannabinoids?
Human, reptiles, birds, and fish all synthesize endocannabinoids (research is still being done on invertebrates) naturally. In fact, the prefix “endo,” literally means “made in the body.”
Endocannabinoids are part of the more extensive endocannabinoid system that regulates appetite, pain sensation, mood, memory, and so much more.
There are three essential parts to the endocannabinoid system:
- Endocannabinoids (anandamide, 2-arachidonoylglycerol (2-AG), n-arachidonoyl dopamine (NADA), and virodhamine (OAE))
- Endocannabinoid receptors (CB1 and CB2)
- Endocannabinoid-moderating enzymes (such as MAGL and FAAH)
For the full article please click here.